XTL, Cubist complete first review of Phase 2 clinical trial of hepatitis B drug

Globes correspondent, "XTL, Cubist complete first review of Phase 2 clinical trial of hepatitis B drug: The monitoring board for HepeX-B, developed by XTL Biopharmaceuticals and Cubist Pharmaceuticals, recommended the trial continue." (23 Nov. 2004, Globes Online)
Leading text: "Cubist Pharmaceuticals, Inc. (CBST) and XTL Biopharmaceuticals (LSE:XTL) today announced the completion of the first scheduled review of the first group of 15 patients enrolled in an ongoing Phase 2 clinical trial. The trial is the second of two planned Phase 2 trials. Based upon a review of the data provided by XTL, a data and safety monitoring board convened by Duke Clinical Research Institute at Duke University, has recommended continuation of the trial. Patients are currently being enrolled in the trial in the U.S. and in Israel. Centers in several Western European countries will be opened shortly..." [FullText]